Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$3.03
-1.6%		$2.41
$0.91
▼
$4.20
$535.41M1.38486,042 shs138,153 shs
LIFE
Ethos Technologies Inc. Class A Common Stock
$38.64
-2.0%		$24.74
$9.45
▼
$40.97
$2.51BN/A1.82 million shs1.09 million shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.64
+0.6%		$1.20
$0.16
▼
$2.54
$95.26M0.8223.01 million shs9.48 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-3.45%-4.35%-5.52%+128.15%+57.14%
LIFE
Ethos Technologies Inc. Class A Common Stock
+0.84%+17.66%+109.79%+108.68%+3,943,999,900.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+2.86%-5.20%-29.08%-12.18%-73.06%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$3.03
-1.6%		$2.41
$0.91
▼
$4.20
$535.41M1.38486,042 shs138,153 shs
LIFE
Ethos Technologies Inc. Class A Common Stock
$38.64
-2.0%		$24.74
$9.45
▼
$40.97
$2.51BN/A1.82 million shs1.09 million shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.64
+0.6%		$1.20
$0.16
▼
$2.54
$95.26M0.8223.01 million shs9.48 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-3.45%-4.35%-5.52%+128.15%+57.14%
LIFE
Ethos Technologies Inc. Class A Common Stock
+0.84%+17.66%+109.79%+108.68%+3,943,999,900.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+2.86%-5.20%-29.08%-12.18%-73.06%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2.00
Hold$9.00197.03% Upside
LIFE
Ethos Technologies Inc. Class A Common Stock
2.71
Moderate Buy$32.29-16.44% Downside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.20
Hold$5.20706.33% Upside

Current Analyst Ratings Breakdown

Latest ENTX, OTLK, and LIFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/14/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
8/12/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$33.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$27.00 ➝ $33.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$27.00 ➝ $33.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$27.00 ➝ $37.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$26.00 ➝ $32.00
7/28/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$40K13,167.62N/AN/A$0.04 per share75.75
LIFE
Ethos Technologies Inc. Class A Common Stock
$387.61M6.36$1.19 per share32.38$7.47 per share5.17
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.35M70.98N/AN/A($0.07) per share-9.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$11.44M-$0.35N/AN/AN/AN/A-147.19%-103.22%11/13/2026 (Estimated)
LIFE
Ethos Technologies Inc. Class A Common Stock
$71.15M-$2.85N/A30.43N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$62.42M-$0.77N/AN/AN/AN/AN/A-254.82%N/A

Latest ENTX, OTLK, and LIFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q3 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.08-$0.09-$0.01-$0.15$0.97 million$0.01 million
8/7/2026Q2 2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.08-$0.14-$0.06-$0.14N/AN/A
8/3/2026Q2 2026
LIFE
Ethos Technologies Inc. Class A Common Stock
$0.19$0.53+$0.34$0.30N/A$189.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
LIFE
Ethos Technologies Inc. Class A Common Stock
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A
8.98
8.98
LIFE
Ethos Technologies Inc. Class A Common Stock
N/A
4.18
4.18
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.81
0.63

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
LIFE
Ethos Technologies Inc. Class A Common Stock
61.72%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
10.57%
LIFE
Ethos Technologies Inc. Class A Common Stock
3.70%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
20173.83 million155.46 millionOptionable
LIFE
Ethos Technologies Inc. Class A Common Stock
61463.76 million61.40 millionN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
20148.59 million145.91 millionOptionable

Recent News About These Companies

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
August 27 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352397/0/en/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-prepares-for-u-s-commercial-launch-of-lytenava.html
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27 at 9:01 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352076/0/en/outlook-therapeutics-ceo-bob-jahr-participates-in-the-virtual-investor-why-now-on-demand-conference.html
FY2026 EPS Estimates for Oncobiologics Boosted by Analyst
August 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30977274
Analysts Offer Predictions for Oncobiologics Q1 Earnings
August 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975782
Analysts Issue Forecasts for Oncobiologics FY2026 Earnings
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analysts-issue-forecasts-for-oncobiologics-fy2026-earnings-2026-08-21/
Brookline Capital Markets Comments on Oncobiologics Q1 Earnings
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brookline-capital-markets-comments-on-oncobiologics-q1-earnings-2026-08-20/
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975675/otlk-q3-earnings-call-maps-lytenava-u-s-launch-and-sales-ramp?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2975675
Short Interest in Oncobiologics, Inc. (NASDAQ:OTLK) Grows By 78.0%
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-oncobiologics-inc-nasdaqotlk-grows-by-780-2026-08-17/
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
August 15, 2026  |  defenseworld.netD
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-08-15/
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Brokerages
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-inc-nasdaqotlk-given-average-rating-of-hold-by-brokerages-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Downgraded to "Sell" Rating by Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-downgraded-to-sell-rating-by-wall-street-zen-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Director Ghiath Sukhtian Buys 2,525,252 Shares of Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-director-ghiath-sukhtian-buys-2525252-shares-of-stock-2026-08-14/
Oncobiologics (NASDAQ:OTLK) Releases Earnings Results
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-releases-earnings-results-2026-08-14/
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936801-outlook-therapeutics-inc-otlk-q3-2026-earnings-call-transcript
Oncobiologics' (OTLK) Buy Rating Reaffirmed at BTIG Research
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-otlk-buy-rating-reaffirmed-at-btig-research-2026-08-14/
Oncobiologics Q3 Earnings Call Highlights
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-q3-earnings-call-highlights-2026-08-14/
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974790/outlook-therapeutics-inc-otlk-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2974790
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345250/0/en/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-and-provides-business-update-highlighting-fda-approval-of-lytenava.html
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
August 14, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts?utm_source=snapi
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344189/0/en/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-and-warrants.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$3.03 -0.05 (-1.62%)
As of 04:00 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Ethos Technologies Inc. Class A Common Stock NASDAQ:LIFE

$38.64 -0.80 (-2.03%)
As of 04:00 PM Eastern

Ethos Technologies Inc operates a technology-driven, direct-to-consumer platform for the distribution of life insurance products. Through its digital underwriting, data analytics, and proprietary technology, it enables consumers to explore, compare, and purchase life insurance policies online. The platform serves consumers, agents, and insurance carriers, and supports the application and policy issuance process through an online interface. The company works with insurance carriers to offer life insurance products in the United States through digital channels and independent agents. It generates revenue through commissions paid by carriers from policies activated and sold through its platform as well as from the provision of third-party administrator services for such policies.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.64 +0.00 (+0.59%)
As of 04:00 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas